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Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well-
established treatment for menopausal symptoms. High quality evidence conﬁ  rms that estrogen 
effectively treats hot ﬂ  ushes, night sweats and vaginal dryness. Progestins are combined with 
estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot ﬂ  ushes, 
but are less effective than estrogen for this purpose. Data are conﬂ  icting regarding the role of 
androgens for improving libido and well-being. The synthetic steroid tibolone is widely used 
in Europe and Australasia and effectively treats hot ﬂ  ushes and vaginal dryness. Tibolone may 
improve libido more effectively than estrogen containing HT in some women. We summarize 
the data from studies addressing the efﬁ  cacy, beneﬁ  ts, and risks of androgens, progestins and 
tibolone in the treatment of menopausal symptoms.
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Introduction
Therapeutic estrogens include conjugated equine estrogens, synthetically derived 
piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol 
valerate.
Estradiol may also be given transdermally as a patch or gel, as a slow release 
percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens 
include topical estradiol in the form of a ring or pessary, estriol in pessary or cream 
form, dienoestrol and conjugated estrogens in the form of creams.
In some countries there is increasing prescribing of a combination of estradiol, 
estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private 
compounding pharmacists. The efﬁ  cacy, safety, and pharmacodynamic proﬁ  le of these 
lozenges are unknown and should not be recommended for clinical use.
Progestins are synthetic analogues of progesterone that have been developed to 
overcome the problems of poor oral absorption of progesterone and its rapid ﬁ  rst-pass 
metabolism in the liver.
Androgens are steroids based on the structure of testosterone. Parenteral 
testosterone has a very short duration of action and oral bioavailability is negligible. 
Topical, implantable, and depot testosterone formulations and synthetic orally active 
androgens have been developed.
Tibolone (Livial®; Organon, Oss, Netherlands) is prescribed in over 70 countries 
for the treatment of menopausal symptoms and prevention of osteoporosis. Classiﬁ  ed 
as a selective tissue estrogenic action regulator (STEAR), it is a synthetic steroid that 
has various metabolites with tissue-speciﬁ  c estrogenic, progestinic, and androgenic 
actions (Albertazzi et al 1998).Clinical Interventions in Aging 2008:3(1) 2
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Menopausal symptoms
The vast majority of women going through menopause will 
experience symptoms related to the hormonal changes during 
this transition. Of these, vasomotor symptoms such as hot ﬂ  ushes 
and night sweats are the most characteristic, and are the main 
reason why women seek treatment (Kronenberg 1994).
Vasomotor symptoms
Vasomotor symptoms, in particular hot ﬂ  ushes, are the most 
characteristic manifestation of the menopause, occurring 
in almost 80% of women of whom about 20% ﬁ  nd them 
intolerable (WHO 1966; Kronenberg 1990).
Hot ﬂ  ashes are described as the sudden sensation of heat 
over the body, particularly in the face, neck, or chest and can be 
accompanied by sweating, ﬂ  ushing, palpitations and anxiety. 
Night sweats may occur with hot ﬂ  ashes or independently and 
can disrupt sleep. Approximately one third of women will 
continue to have vasomotor symptoms for up to ﬁ  ve years 
and some women for even longer (Kronenberg 1990).
Estrogen (ET) and estrogen – progestin 
therapy (EPT)
Estrogen is generally prescribed and as single therapy to 
hysterectomized women and combined with a progestin 
in women with an intact uterus to prevent endometrial 
hyperplasia.
Hormone therapy is highly effective in the treatment of 
menopausal vasomotor symptoms. In quality randomized, 
placebo controlled trials, estrogen alone reduces vasomotor 
symptoms by 65% (OR 0.35, 0.22–0.56) and combined HT 
by 90% (OR 0.10, 0.06–0.19). Hence, whilst direct comparative 
trials are lacking, combined HT appears to be more effective 
at treating vasomotor symptoms than estrogen alone (Slowinska-
Srzednicka et al 1992). Importantly, the mean placebo effect 
was 51% in these trials. Alternative treatments for vasomotor 
symptoms must be compared against this high placebo 
response, which may be partly due to symptom ﬂ  uctuation 
around perimenopause and gradual resolution of symptoms 
post-menopause (Slowinska-Srzednicka et al 1992).
Oral estrogen therapy increases the plasma protein sex 
hormone binding globulin (SHBG) to a greater extent than 
non-orally administered estrogens (Pasqualini et al 1996) 
and this may result in a clinically signiﬁ  cant reduction in the 
bioavailability of sex steroids, including testosterone.
Progestins
Progestins delivered via a variety of routes are effective in 
the treatment of menopausal hot ﬂ  ashes. Oral progestins 
are superior to placebo in treating hot ﬂ  ashes, but are less 
effective than estrogen (Prestwood et al 2003). Progestins 
do not affect clotting factors and hence may be an option for 
women at increased risk of thrombosis (Schindler 2003).
Reduction in vasomotor symptoms has been demonstrated 
with daily doses of 10 to 20 mg of oral medroxyprogesterone 
acetate (MPA) and 20 mg twice a day of oral megestrol 
acetate (Schiff et al 1980; Loprinzi et al 1994). Depo 
medroxyprogesterone acetate is effective in treating hot 
ﬂ  ashes in breast cancer patients (Loprinzi et al 2006), but the 
safety of DMPA after breast cancer is not established.
The evidence of whether transdermal progestins are 
effective in treating menopausal hot ﬂ  ashes is conﬂ  icting 
(Leonetti et al 1999; Wren et al 2003).
Concerns about the use of progestin include the 
observation from large randomized controlled trials (RCTs) 
that the addition of progestins to estrogen might increase the 
risk of breast cancer (Rossouw et al 2002). Also, the addition 
to progestin to estrogen in menopausal HRT increases breast 
density at mammography and increased breast density is a 
risk factor for breast cancer (Warren 2004).
Progestins vary in their clinical effects and endocrine 
properties (see Table 1). This may also impact on their efﬁ  cacy 
and side effects in the management of menopausal symptoms.
Tibolone
Tibolone is a synthetic prohormone with weak estrogenic, 
progestinic, and androgenic actions. It does not stimulate 
the endometrium so additional progestins are not required. 
A dose-ﬁ  nding study demonstrated that tibolone was sig-
niﬁ  cantly more effective than placebo for the management 
of hot ﬂ  ushes and sweating, and reported that a daily dose of 
Table 1 Biological activities of progesterone and progestins
Progestin  Anti E   E  A  Anti A  Gluco  Anti min
Progesterone  +  −  −  ±  +  + 
Dydrogesterone  +  −  −  ±  −  ± 
17α-OH-derivatives
Cyproterone acetate  +  −  − +  +  +  −
MPA  +  −  ±  −  +  −
Spironolactone 
derivatives
Drospirenone  +  −  −  +  −  +
19-nortestosterone 
derivatives
Norethisterone  +  +  +  −  −  −
Levonorgestrel  +  −  +  −  −  −
Dienogest  ±  ±  −  +  −  −
Derived from Schindler et al (2003).
Abbreviations: Ant E, anti-estrogenic; E, estrogenic; A, androgenic; Anti A, ant-
androgenic; Gluco, glucocorticoid;   Anti min, antimineralocorticoid.Clinical Interventions in Aging 2008:3(1) 3
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2.5 mg was clinically optimal with respect to symptom relief, 
adverse events, and acceptability (Landgren et al 2002). There 
are limited data comparing tibolone with estrogen-containing 
HRT, but in small studies tibolone effectively reduces hot 
ﬂ  ashes and improves vaginal dryness with a similar efﬁ  cacy 
to estrogen (Baracat 2002; Modelska and Cummings 2002). 
Tibolone does not increase mammographic density (Valdivia 
et al 2004). Unlike estrogen, tibolone reduces SHBG, and 
hence may increase free circulating testosterone. This effect 
plus tibolone’s androgenic properties are believed to enhance 
sexual function to a greater extent than ET/EPT (Egarter et al 
2002). However, this is yet to be demonstrated with validated 
instruments in an adequately powered RCT. Tibolone increases 
bone density but fracture data are not yet published.
Tibolone suppresses the endometrium and is associated 
with fewer days of bleeding and spotting than combined 
HRT (Archer 2007).
A signiﬁ  cant fall in HDL cholesterol can occur with 
tibolone therapy. The clinical implication of the effect of 
tibolone on lipid metabolism and hemostasis is unclear. 
Deﬁ  nite conclusions with regard to risks for cardiovascular 
disease or venous thromboembolism cannot be drawn from 
trials to date and long-term effects are unknown.
Data from the Million Women study suggested that current 
use of tibolone is associated with an increased risk of breast and 
endometrial cancer than that seen with nonusers or previous 
users. Although these ﬁ  ndings have been questioned because of 
likely selection bias due to prescribing practices and conﬁ  rmation 
in a randomised controlled trial is required (Million Women 
Study Collaborators 2003, 2005). Preliminary data suggested that 
tibolone may be safely used following breast cancer (Antoine 
et al 2007), but this has not been conﬁ  rmed in larger scale 
randomised controlled trials (www.organon.com).
Sexual dysfunction
Sexual difﬁ  culties are complex in origin. Poor arousal, vaginal 
dryness, dyspareunia, and orgasmic difﬁ  culties are more 
common in the menopausal years. Simple vaginal lubricants 
and moisturisers, psychological intervention, counseling, or sex 
therapy should be considered. There is a paucity of evidence 
on the effect of progestins alone on sexual functioning.
Androgens
RCTs have demonstrated improvement in measurements 
of sexual function with various types of combined 
estrogen – testosterone compared with estrogen alone or placebo.
As stated above, trials of women with spontaneous and 
surgical menopause showed improvement in self-reported 
sexual enjoyment, desire, and arousal when testosterone 
was added to ET/EPT (Dow et al 1983; Sherwin et al 1985; 
Davis et al 1995; Sarrel et al 1998; Shifren 2002; Lobo et al 
2003)
RCTs of women with surgical menopause demonstrated 
increased sexual desire and frequency of satisfying sexual 
activity in women using 300mcg daily testosterone patches 
(Braunstein et al 2000; Buster et al 2005).
It has been suggested that to be effective, androgen levels 
must be increased above normal (Cameron and Braunstein 
2004).
Total and free testosterone levels decline with age, prior 
to the menopause (Paganini-Hill and Henderson 1989) and do 
not vary across the menopause transition in healthy women 
(Green et al 1996). However, oophorectomy is associated 
with a signiﬁ  cant decline in circulating testosterone levels 
(Beresford et al 1997).
Testosterone
Testosterone is the most potent female androgen. The primary 
indication for the use of supplemental testosterone has been 
the treatment of low libido in post-menopausal women. 
However, the question of whether there is a syndrome of 
female androgen insufﬁ  ciency and whether supplementary 
androgens have a beneﬁ  cial effect on libido, energy or sense 
of wellbeing in pre and postmenopausal women remains 
unresolved. In the absence of high quality evidence expert 
opinion is divided. Whilst some high quality RCTs have 
demonstrated that increases in total and free testosterone 
in the physiologic range in postmenopausal women are 
associated with improvement in sexual satisfaction, general 
well-being, and mood. (Davis et al 2006), other studies have 
not conﬁ  rmed this. There has been a lack of standardization 
in the measurement of female sexual function which makes 
direct comparisons between studies difﬁ  cult.
A recent consensus statement from the Endocrine 
Society recommend against making a diagnosis of androgen 
deﬁ  ciency in women at present because of the lack of a well-
deﬁ  ned clinical syndrome and normative data on total or free 
testosterone levels across the lifespan that can be used to 
deﬁ  ne the disorder. They recognized that there is evidence 
for short-term efﬁ  cacy of testosterone in selected populations, 
such as surgically menopausal women, but advised against 
the generalized use of testosterone by women, because the 
indications are inadequate and evidence of safety in long-term 
studies is lacking (Wierman et al 2006). In contrast, other 
expert groups have argued there are ample data to suggest that 
adrenal androgens play a role in the development of axillary Clinical Interventions in Aging 2008:3(1) 4
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and pubic hair, and that testosterone is critical for women’s 
libido and sexual function (Traish et al 2007).
In addition, there are a number of practical restrictions 
to the diagnosis and management. No lower limit of total or 
free testosterone has been shown to be diagnostic of female 
androgen insufﬁ  ciency and there is no “normal range” for 
postmenopausal women. Further, most available assays are 
unable to accurately measure testosterone in the lower female 
range. Most circulating testosterone is protein-bound but 
only the free fraction is clinically active. Hence an estimate 
of free testosterone is thought to be the most useful measure 
of endogenous testosterone levels. However, commonly 
available direct free testosterone assays are notoriously 
imprecise (Wells et al 2002), and it is generally agreed that 
free testosterone is most reliably calculated by the laboratory 
using the Sodergard equation if both total testosterone and sex 
hormone binding globulin are known (Riphagen 2000).
A further confounding factor for clinical practice is that 
circulating estrogen levels will impact on free testosterone 
via an increase in SHBG. Most investigators recommend 
that androgen therapy should be offered only when the 
patient continues to have problems while receiving adequate 
estrogen replacement therapy (Braunstein 2002).
Since the measurement of serum testosterone is fraught, 
the main indication for measurement should be to exclude 
women from therapy because of a mid range or higher 
testosterone value or to ensure that levels do not become 
supraphysiological if exogenous androgens are prescribed.
The decision to prescribe testosterone to a woman 
needs to be based upon clinical assessment, which includes 
exclusion of factors such as fundamental relationship 
difﬁ  culties, clinical depression and other common causes 
of low wellbeing during midlife such as iron deﬁ  ciency 
and thyroid disease. Testosterone preparations include a 
transdermal patch, cream, gel, and spray.
Safety data for testosterone and combined estrogen-
androgen therapy in postmenopausal women are lacking. 
High levels of endogenous testosterone (and estrogen) in 
postmenopausal woman are linked with an increased risk 
of breast cancer. (Hankinson and Eliasson 2007) and there 
are no data from large RCTs on the effects of supplemental 
testosterone on breast cancer risk. Side effects of exogenous 
testosterone include acne and hirsutism. Long-term use may 
be associated with adverse clinical and metabolic as well as 
cosmetic effects. A decrease in HDL cholesterol has been 
documented with the addition of methyltestosterone and 
testosterone implants to hormonal therapies (Castelo-Branco 
et al 2000; Somboonporn et al 2005).
DHEA
Dehydroepiandrosterone (DHEA) is a female androgen 
increasingly available commercially as a supplement aimed at 
improving libido and well-being in post-menopausal women. 
However, there is scant evidence to support the use of DHEA 
for this purpose, and safety data for DHEA therapy are 
lacking. DHEA and its sulfate DHEAS are the most abundant 
circulating sex steroid hormones in women, providing a 
large precursor reservoir for the intracellular production of 
androgens and oestrogens in non-reproductive tissues. Levels 
of DHEA and DHEAS decline with age. In premenopausal 
women, levels of DHEA correlate with feelings of vitality 
(Bell et al 2006). It has been proposed that restoring the 
circulating levels of these steroids to those found in young 
people may have anti-aging effects and improve well-being 
and sexual function. However, this is not supported by the 
published literature and there is currently no clear clinical 
role for DHEA (Panjari and Davis 2007).
Vaginal dryness
Approximately 50% of post menopausal women suffer 
symptoms of urogenital atrophy. This may include vaginal 
dryness, dyspareunia and recurrent urinary tract infections 
(Maclennan et al 2002; Boothby et al 2004). Topical 
(vaginal) estrogen effectively relieves vaginal dryness 
and atrophy. However, although the urogenital tract is 
estrogen sensitive, urinary incontinence may not respond to 
systemic estrogen and observational data from the Nurses 
Health Study suggests that hormone therapy may even 
worsen urinary incontinence (Cardozo et al 1998; Simpson 
et al 2000).
Neither androgens nor progestins have been shown to 
improve vaginal dryness or improve urogenital symptoms. 
For women with vaginal dryness who wish to avoid 
hormones, vaginal lubricants such as Replens® (Warner-
Lambert, Morris Plains, NJ) may be helpful, but are not as 
effective as topical estrogens. (Nachtigall 1994; Bygdeman 
and Swahn 1996)
Tibolone
RCTs assessing the effects of tibolone on sexual function have 
demonstrated signiﬁ  cant improvement in the physiological 
aspects of sexual function in postmenopausal women, 
including those who have undergone bilateral oophorectomy, 
such as vaginal blood ﬂ  ow and vaginal lubrication. They 
have also reported increased sexual interest and desire in 
postmenopausal women taking tibolone compared with 
placebo (Laan and van Lunsen 2001; Egarter et al 2002).Clinical Interventions in Aging 2008:3(1) 5
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In two other trials, tibolone was compared with combined 
estradiol-norethisterone acetate (E2/NETA). Scores measur-
ing improvement of sexual function with regard to frequency, 
satisfaction, and enjoyment was higher in women taking 
tibolone versus those taking E2/NETA (Nathorst-Böös and 
Hammar 1997; Doren et al 2001).
If tibolone improves sexual function, it will be important 
to determine whether it does so by increasing free testosterone 
in women with low testosterone concentrations or in all 
women regardless of androgen levels (Modelska and 
Cummings 2002).
Mood and cognitive disturbances
A range of other symptoms, including depression, 
nervousness, agitation, insomnia, arthralgia, and poor 
concentration are associated with the menopause 
(Bachmann 1998), but the relationship between these 
symptoms and low estrogen is more difﬁ  cult to determine. 
Such psychological and mood changes around the time 
of menopause may be the result of a complex interplay 
between environmental stimuli and other factors such 
as sleep disturbance and fatigue. Sleep disturbance is 
a pervasive and distressing menopausal symptom and 
may occur independently of hot ﬂ  ushes and night sweats 
(Cardozo et al 1998). A community-based longitudinal 
study gave no support for mood symptoms being part of 
the menopausal syndrome (Avis et al 1994; Baker 1994; 
Khan et al 1994; Dennerstein et al 2004).
Any improvements in these symptoms or in general 
wellbeing noted while taking ET/EPT may be due to 
improvements in vasomotor symptoms, urogenital symptoms, 
sexual function, and quality of sleep (Brown et al 2001).
Findings of observational studies suggest that hormone 
therapy could improve or preserve cognitive function in 
women with and without dementia, respectively (McBee 
et al 1997; Carlson et al 2001; Lokkegaard 2002). 
Furthermore, results of a meta-analysis (Le Blanc et al 2001) 
indicate that women with menopausal symptoms who take 
ET/EPT have better verbal memory, vigilance, reasoning, 
and motor speed, than those who do not. However, initiation 
of ET/EPT in women older than age 65 years did not prevent 
dementia or enhance cognition in the primary prevention 
of dementia part of WHI (WHIMS) (Espeland et al 2004; 
Shumaker et al 2004), but was instead associated with an 
increased rate of cognitive decline compared with placebo 
(Shumaker et al 2003).
Data from RCTs (Mulnard et al 2000) of women with 
established dementia indicate that ET/EPT neither increases 
disease progression nor improves symptoms. The cognitive 
response to HRT might vary according to genotype; only 
individuals who do not carry the apolipoprotein E (APOE) 
genotype (the major genetic risk factor for Alzheimer’s 
disease) are protected by hormone therapy (Burkhardt et al 
2004). Whether these observations about mental state and 
HRT can be applied to women of all ages and irrespective 
of different estrogen/progestin combinations or modes of 
delivery is not known.
Generally, hormone therapy should not be recommended 
for the preservation of cognitive function or the prevention 
of dementia (Andrews et al 2004; Naftolin et al 2004; 
RANZCOG 2004). Furthermore, women aged older than 
65 years should be made aware that commencement of ET/
EPT at such a late stage could result in a worsening of their 
cognitive capacity (Naftolin et al 2004).
There is little evidence of the beneficial effects of 
testosterone on mood or sense of well-being. One study 
measured improvements in well-being scores in women with 
surgically induced menopause using 300 mcg testosterone 
patches with oral conjugated equine estrogens (The North 
American Menopause Society 2005; Somboonporn et al 
2005). One small trial of cognition in postmenopausal women, 
using building memory tasks, reported a decline in scores in 
women using ET but a maintenance in those using combined 
oral estrogen-methyltestosterone (Wisniewski et al 2002).
Progestins may lead to increased adverse effects on mood 
when added to estrogen therapy, in a dose-dependent manner 
(Sherwin 1991). Another study has shown that addition of 
progestins improved memory above what was obtained by 
estrogen alone. They conclude that the effect did not depend 
on improvement of mood since the latter worsened during 
the progestinic phase of EPT (Natale et al 2001).
Published studies have reported beneﬁ  cial effects of 
tibolone on mood (Ross et al 1999; Davis 2002).
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